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Abstract
Background: Current detection or screening for malaria infection necessitates drawing blood by
fingerprick or venipuncture, which poses risks and limitations for repeated measurement. This
study presents PCR detection of Plasmodium falciparum in human urine and saliva samples, and
illustrates this potential application in genotyping malaria infections.
Methods: Urine and saliva were obtained from 47 thick film positive and 4 negative individuals one
day after collection of blood slides and filter paper blood spots. P. falciparum DNA was extracted
from blood, urine and saliva, in separate groups, using the Chelex method or Qiagen DNEasy® kit
(urine and saliva only). Blood, urine and saliva extracts were subjected to PCR in separate batches.
Amplicons from the various sample types were examined for MSP2 polymorphisms and restriction
fragment patterns on DHFR amino acid codon 59.
Results and discussion: Malaria infections exhibited primarily low-grade parasite densities, with
a geometric mean of 775 asexual parasites/μl. Regularly matching polymorphic MSP2 genotypes
were found between the corresponding urine, saliva and peripheral blood amplicons of each
individual, with different inter-individual polymorphic genotypes. Amplicon yields were significantly
dependent on DNA extraction method, parasite density and primer set (p < 0.001). A Qiagen® kit
extraction had more than 2× higher amplicon yield than the Chelex method, for both urine and
saliva. Amplicon yields were 1.6 fold higher from saliva than urine. For each unit increase in log
parasite density, the probability of amplicon enhanced 1.8 fold. Highest amplicon yields were
obtained from the primer set with the shortest PCR product.
Conclusion: P. falciparum infection is detectable by PCR on human urine and saliva samples.
Subject to further refinement of extraction technique and amplicon yields, large-scale malaria
parasite screening and epidemiological surveys could be possible without the need to collect blood
and use of needles or sharps.
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Background
Endemic countries are adopting more effective strategies
and treatment regimens for malaria control, through pub-
lic-private sector initiatives such as the RBM [1]. As sub-
stantial impact is brought to bear on this formidably
resilient disease [2,3], the increased importance of accu-
rate diagnosis, epidemiological surveillance and research
cannot be overemphasized. Use of efficient molecular
tools is becoming widely integrated to afford more
informative and comparable results in programmes such
as national drug therapeutic efficacy monitoring [4,5].
Molecular genotyping by national drug therapeutic effi-
cacy monitoring programmes to distinguish post-treat-
ment recrudescence from new infections is becoming
universal standard [6].
In accord with current knowledge of the parasite life cycle,
detection or screening for malaria infection presupposes
the drawing of blood by finger prick or venipuncture. The
need to draw blood causes difficulties in certain commu-
nities with blood taboos and poses limitations for
repeated measurement, especially in young children, who
experience the highest malarial burden and constitute the
mainstay sentinel group for most malaria epidemiological
surveys. Inevitable use of needles or sharps poses a bio-
hazard as well as extra workload and cost in field situa-
tions. The present study describes the use of urine and
saliva samples for PCR detection of Plasmodium falciparum
infection and illustrates potential application in genotyp-
ing malaria parasites.
Methods
Study area and population
The study was conducted in the vicinity of the Malaria
Institute at Macha (MIAM), located 80 km north of
Choma, in the southern province of Zambia. The resident
population, which is estimated at 180,000, comprises
subsistence farmers of the Batonga tribe. Willing subjects
of all ages were included in the study.
Study design and data collection
This prospective cross-sectional study explored the
hypothesis that P. falciparum infection detectable by PCR
on peripheral blood is also detectable by PCR on urine or
saliva from the same human host. By prior appointment
through local chiefs and headmen, communities assem-
bled at central designated points of their choice, for
malaria screening by microscopy. Thick films and filter
paper (Whatman No 3 MM) blood blots were collected,
with recording of axillary temperature and history of
symptoms in the past 48 hours. Slides were examined at
MIAM, followed by feedback to the community, including
treatment of positives, the following day. On the day of
feedback, whole urine and saliva samples (5 ml) were col-
lected from all willing positive individuals, in sterile
tubes, while some were blotted onto filter paper cuttings.
The whole urine or saliva specimens were subsequently
aliquoted into 1 ml replicate amounts in microcentrifuge
tubes at the laboratory and either immediately extracted
or stored at -20°C for later extractions. Additional blood
samples were also collected on filter paper. Separate dry-
ing boards were used for urine, saliva and blood filter
paper blots.
P. falciparum DNA extraction
Chelex extractions
(a) Filter paper blots
Filter paper blots of saliva, urine and blood were extracted
using the Chelex method [7,8].
(b) Whole urine and saliva
Whole urine or saliva (1 ml) was spun in a 1.5 ml micro-
centrifuge tube for three minutes at 14,000 rpm. The
supernatant was aspirated out to the 0.1 ml mark and dis-
carded. The pellet was then re-suspended in 1 ml of 1×
PBS/1% saponin solution by gentle tapping and vortex-
ing, and left at room temperature for 20 minutes. Follow-
ing lysis, the sample material was spun for two minutes at
14,000 rpm and the supernatant aspirated and discarded.
The pellet was re-suspended in 1 ml of 1× PBS, followed
again by spinning for two minutes at 14,000 rpm. After
aspirating and discarding of supernatant, a 100 μl suspen-
sion of 20% Chelex in autoclaved PCR-grade water was
added and mixed thoroughly with the pellet. The mixture
was then boiled for 13 minutes and finally spun for three
minutes, at 14,000 rpm. The resultant supernatant, con-
taining DNA, was carefully transferred into a pre-labelled
1.5 ml microcentrifuge tube, excluding Chelex, for imme-
diate PCR, or stored at -20°C.
Commercial kit extraction (Qiagen DNeasy® purification kit)
Whole urine or saliva sample (1 ml) was spun for 3 min-
utes at 14,000 rpm. After aspirating and discarding super-
natant, DNA was extracted using the crude cell lysates
protocol following the manufacturer's instructions. Kit
Buffer ATL® (200 μl) was used for the initial lysis step on
the pellet and final DNA elution was carried out in 100 μl
volumes.
Genotyping of Plasmodium falciparum in urine and 
saliva
P. falciparum genotyping was performed on blood, urine
and saliva extracts using nested PCR and MSP2 family-
specific primers [9]. Nested PCR and allele-specific restric-
tion enzyme digestion were employed for typing DHFR
amino acid codon 59[10]. For comparison with standard
DHFR primers, additional primer sets (U1/U2, U3/U4)
were designed on the DHFR domain that define shorterMalaria Journal 2006, 5:103 http://www.malariajournal.com/content/5/1/103
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primary (370 bp) and secondary (229 bp) amplicon
(Table 1).
Primary and secondary PCR reactions for all loci were run
in 25 μl volumes comprising 2 μl template (0.5 μl for lab-
oratory standard clone genomic DNA), 0.25 μM primers
(0.2 μM for MSP2), 1.5 mM magnesium chloride, 200 μM
dNTP's, 1× PCR Buffer and 1U of Taq DNA polymerase.
PCR annealing cycles for both primary and secondary
MSP2 reactions comprised an initial two minute denatur-
ation step at 94°C, followed by 25 cycles of denaturation
at 94°C for 45 seconds, annealing at 61.1°C for 45 sec-
onds and extension at 65°C for one minute. Final exten-
sion was at 65°C for two minutes. Annealing cycles for
both both primary and secondary DHFR amplification
consisted of initial denaturation at 94°C for two minutes,
followed by 25 cycles of denaturation at 94°C for 45 sec-
onds, annealing at 43.4°C for 45 seconds and extension
at 65°C for one minute. The final extension step was at
65°C for two minutes. The PCR amplifications were per-
formed in a Thermo Electron®  PX2 (HBPX2) thermal
cycler. Polymorphisms and restriction fragment patterns
were resolved by electrophoresis on 1.5% agarose gel (12
μl of sample per lane) and visualized by UV transillumi-
nation. Product for 3D7/IC and FC27 family-specific
primers was run on separate gels to score amplicon yields.
To facilitate between-sample comparison of MSP2 poly-
morphic patterns, the 3D7/IC and FC27 product was then
loaded in duplex for each sample and run on a fresh set of
gels.
Ethics
The study was approved by the national and Johns Hop-
kins University IRB as part of a baseline geographical and
malariometric reconnaissance project at Macha. Patient
participation was by informed consent of the patients
themselves or guardians, in the case of children.
Results
The 51 cases from whom assay samples derived consisted
of 47 microscopy-positive and four microscopy negative
individuals, aged from 1–54 years (median 11.0 years).
Of the 47 that were positive by microscopy, malarial infec-
tions exhibited low-grade parasite density, with a median
of 708 asexual parasites/μl (geometric mean [95% CI]:
775 [417–1439] asexual parasites/μl; range: 37 – 123026
asexual parasites/μl). All the infected individuals were
asymptomatic, except for two febrile cases whose infec-
tions had the highest parasite density (mean axillary tem-
perature, 36.85°C; median, 36.90°C; range: 35.60°C –
41.00°C).
MSP2 genotyping of P. falciparum on urine and saliva 
samples
Saliva, urine and blood extracts were subjected to nested
PCR in separate batches using MSP2 family-specific prim-
ers and then loaded in adjacent lanes for each patient dur-
ing electrophoresis. Amplicons from saliva and urine
extracts exhibited MSP2 polymorphic patterns as well as
multiplicity of infection that was regularly identical to
blood sample extracts from the same individual (Figure 1
and 2). As expected MSP2 amplicons from different
patients were polymorphic (Figure 2).
P. falciparum DHFR genotyping on urine and saliva 
samples
As with MSP2 polymorphisms, restriction fragment
results for the DHFR amplicon flanking amino acid codon
59 showed that the infection detected in urine/saliva PCR
was the same as that found in the corresponding blood
amplicon for each individual, whereas between-patient
differences were apparent (Figure 3). The genotyping
results showed more infections with the mutated Arg-59
allele (64.7%) including 17.6% mixed mutated and wild
variants in the same individual.
Amplicon yield
Amplicon yield differed considerably by DNA extraction
method (Additional File 1). Some of the 47 thick-film
positive samples were PCR-negative, with different per-
cent yields amongst primer sets (Additional File 1).
Amongst the four thick film negative field samples two
had positive PCR amplifications.
Aliquots of whole saliva and urine extracted by the Qiagen
commercial kit afforded 2.6× (odds ratio [95% CI]: 2.609
Table 1: Characteristics of primers used in nested PCR on P. falciparum DHFR. Lower case denotes nucleotide mismatch.
Reaction Primer Nucleotide location Product size (bp)
Nest I U1: 5'-GGAAATAAAGGAGTATTACCATG-3' 121..143
U2: 5'-TAAGGTTCTAGACAATATAACA-3' 393..372 273
Nest II U3: 5'-GAAATGTAaTTCCCTAGATATGgAATATT-3' 144..172
U4: 5'-ATTTATCCTATTGCTTAAAGGT-3' 372..351 229
Nest I M1: 5'-TTTATGATGGAACAAGTCTGC-3' 3..18
M5: 5'-AGTATATACATCGCTAACAGA-3' 645..625 643
Nest II F: 5'-GAAATGTAATTCCCTAGATATGgAATATT-3' 144..172
M4: 5'-TTAATTTCCCAAGTAAAACTATTAGAgCTTC-3' 469..439 326Malaria Journal 2006, 5:103 http://www.malariajournal.com/content/5/1/103
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[1.269–5.331], p = 0.008) and 2.3× (odds ratio [95% CI]:
2.289 [1.281–4.091], p = 0.005) better amplification suc-
cess, respectively, than the Chelex approach on corre-
sponding specimens. Saliva extracts generally gave 1.6
fold better amplicon yield than corresponding urine
extracts (odds ratio [95% CI]: 1.559 [1.046–2.324], p =
0.029).
In addition to extraction method, amplicon yield was also
significantly dependent on parasite density and primer
set. For each unit increase in log parasite density, the prob-
ability of amplification increased 1.8 fold (odds ratio
[95% CI]: 1.826 [1.529–2.181], p < 0.001). The DHFR
primer set U1-4 afforded the best amplification success,
while lowest amplicon yields were obtained with FC27,
which was 18.5× less likely to amplify than U1-4. The
FC27 primary amplicon is around 750 bp in length in
contrast to 370 bp for U1-4. Using primers U1-4, the
probability of amplification was not significantly different
between commercial (Qiagen®) kit saliva extracts and
standard chelex-extracted filter paper blood (odds ratio
[95%CI]: 0.522 [0.133–2.049], p = 0.351). For kit-
extracted urine, there was a barely significant difference
(odds ratio [95% CI]: 0.258 [0.068–0.982], p = 0.047).
However, chelex-extracted saliva and urine were still 9.6×
(odds ratio [95% CI]: 0.104 [0.017–0.650], p = 0.015)
and 10.2× (odds ratio [95%CI]: 098 [0.026–0.366], p =
0.001) less likely to amplify, respectively, than corre-
sponding blood extracts.
Discussion
Current malaria detection and epidemiological surveys
depend on drawing blood, which entails risks and often
poses difficulties in young children and certain communi-
ties with blood taboos. Because they are the most vulner-
able to infection and disease, young children tend to
Showing P. falciparum MSP2 amplicon from saliva (173Qs), urine (173Qu, 173u) and blood (173b) samples of patient 173 Figure 1
Showing P. falciparum MSP2 amplicon from saliva (173Qs), urine (173Qu, 173u) and blood (173b) samples of patient 173. Qs 
and Qu denote saliva and urine samples extracted by Qiagen® commercial kit (crude cell lysate protocol), while u denotes 
whole urine sample extracted by the Chelex method. Qs-, Qu-, u- and b-, denote amplicon from corresponding extracts of 
saliva, urine and blood donated by thick film negative healthy control. 3D7, amplicon from positive control laboratory standard; 
M, 100 bp DNA ladder. Extraction of urine replicate sample 173u was performed on 20.02.06, while Qiagen extractions were 
carried out on 09.02.06. Identical MSP2 alleles are apparent in amplicon from urine, saliva and blood samples of patient 173, as 
compared to 3D7 lab standard.
173Qs 173u 173b M Qs - Qu - u - b - 3D7 173QuMalaria Journal 2006, 5:103 http://www.malariajournal.com/content/5/1/103
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constitute the de facto sentinel group used for most
malaria surveys. The present study shows for the first time
that P. falciparum infection can be detected by PCR on
saliva and urine samples from the human host. Nested
PCR with P. falciparum MSP2 family-specific primers illus-
trates that the infection detected in saliva or urine samples
is regularly identical to that found in the corresponding
peripheral blood of the same individual. In contrast,
between-patient MSP2 polymorphic variations were evi-
dent among the study samples.
These findings open up possibilities to obviate the draw-
ing of blood and the use of needles or sharps during large
scale screening or epidemiological surveys for malaria
infection. Potential advantages are also envisaged for
cohort or follow-up studies entailing repeated sampling
or testing for P. falciparum infection. Molecular genotyp-
ing in clinical trials and drug or vaccine efficacy monitor-
ing programmes could be significantly facilitated by such
a bloodless approach. The fact that amplification was
achieved on infections of low-grade parasite density
appears to bode well for potential application of this prin-
ciple.
There is an important need to refine DNA isolation tech-
nique and maximize amplicon yields to attain levels pos-
sible with blood samples. It was clear that apart from
parasite density and extraction method, the locus or
primer set used significantly influenced the probability of
PCR amplification from a given infection. This presuma-
bly reflects differences in primer annealing properties and
PCR conditions. However, it was notable, firstly, that the
PfDHFR primer set U1-4, which flanks the shortest ampli-
con fragment, achieved the highest amplification success.
Secondly, the U1-4 amplicon yields were actually similar
between Qiagen® saliva extracts and blood, and only mar-
ginally different for Qiagen®-extracted urine. This would
seem to suggest that DNA may be degraded in saliva or
urine samples such that chances of amplification are
greater with short PCR fragments. Comparisons with
Amplicon from saliva, urine and blood extracts of field samples 216, 34 and 210 Figure 2
Amplicon from saliva, urine and blood extracts of field samples 216, 34 and 210. Matching MSP2 alleles are seen in saliva (Qs) 
and blood (b) amplicon from each individual. In contrast, between-patient polymorphic differences are evident, reflecting 
diverse infections. Urine samples from these patients did not amplify, except that of 210 (210Qu). Qs, Qu denote Qiagen saliva 
and urine extracts, respectively, by crude lysate approach; Cu denotes Qiagen urine extracts, by cultured animal cells protocol; 
Du denotes Chelex direct extraction on whole urine. Qs-, Cu-, b- were corresponding extracts of saliva, urine and blood sam-
ples from healthy negative control, while 3D7 was positive control laboratory standard.
216Q 210Q 216b 34Qs 34Cu 34b M 210Qu 210b Qs- 216Du Cu- b- 3D7Malaria Journal 2006, 5:103 http://www.malariajournal.com/content/5/1/103
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larger sample sizes would be needed to clearly establish
the relative influence of product length on amplicon out-
come.
Identifying the source of malarial DNA in human urine or
saliva could also aid in development of protocols for max-
imizing amplicon yields and assay detection sensitivity. At
present, the DNA source is still unclear and not directly
inferrable from the current study. Speculations range from
free molecular complexes released by lysed cells, to para-
sites in trace amounts of blood escaping into urine and
saliva. Comparisons of experimental DNA extraction pro-
tocols in this study would seem to suggest an intracellular
origin for the DNA, either in erythrocyes or trapped in
macrophages. Future work will attempt to examine this
aspect.
Conclusion
This study illustrates for the first time, the principle of
detecting P. falciparum infection by PCR on human urine
and saliva samples. Subject to refinement of extraction
technique and amplicon yields, future large scale malaria
screening or epidemiological surveys could be possible
without the need to draw blood or the use of needles or
sharps.
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Xmn I digest of DHFR F-M4 amplicon from saliva, urine and blood samples of patients 7, 15, 17 and 28 Figure 3
Xmn I digest of DHFR F-M4 amplicon from saliva, urine and blood samples of patients 7, 15, 17 and 28. Qs, Qu denotes saliva 
and urine samples extracted by Qiagen® kit (crude cell lysate protocol). Blood samples were extracted on different days by 
Chelex from dry filter paper blots. U is undigested DHFR F-M4 amplicon. Identical restriction fragment patterns are evident on 
different extracts from each patient. Patients 7, 15 and 28 were infected with parasites carrying the mutated (antifolate resist-
ance associated) allele (coding for DHFR Arg-59). Patient 17 carried mixed wild type (Cys-59) and mutated (Arg-59) variants, 
of which the mutated form was barely discernible in the urine amplicon. Incomplete digestion is present in some amplications, 
with a band at 326 bp.
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